These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 22481575

  • 1. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.
    Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J, Oyama T.
    Breast Cancer; 2014 Jan; 21(1):66-74. PubMed ID: 22481575
    [Abstract] [Full Text] [Related]

  • 2. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ, Seo AN, Park SY, Kim JY, Park JY, Yu JH, Ahn JH, Gong G.
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [Abstract] [Full Text] [Related]

  • 3. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
    Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A.
    Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
    [Abstract] [Full Text] [Related]

  • 4. EGFR expression and gene copy number in triple-negative breast carcinoma.
    Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, Guler G.
    Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
    [Abstract] [Full Text] [Related]

  • 5. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ, Heilenkötter U, Geist S, Paluchowski P, Wilke C, Jaenicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, Lebeau A.
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [Abstract] [Full Text] [Related]

  • 6. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
    Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin PM, Colombo PE, Bibeau F, Romieu G, Lamy PJ.
    BMC Cancer; 2015 Dec 18; 15():986. PubMed ID: 26680641
    [Abstract] [Full Text] [Related]

  • 7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.
    BJU Int; 2012 Dec 18; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [Abstract] [Full Text] [Related]

  • 8. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I, Lee A, Vora R, Budman DR.
    Crit Rev Oncol Hematol; 2013 Nov 18; 88(2):284-92. PubMed ID: 23755891
    [Abstract] [Full Text] [Related]

  • 9. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C, Holden JA, Layfield LJ.
    Hum Pathol; 2006 Jun 18; 37(6):755-63. PubMed ID: 16733218
    [Abstract] [Full Text] [Related]

  • 10. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.
    Neuroendocrinology; 2012 Jun 18; 96(3):228-37. PubMed ID: 22378048
    [Abstract] [Full Text] [Related]

  • 11. Molecular alterations in AKT and its protein activation in human lung carcinomas.
    Dobashi Y, Kimura M, Matsubara H, Endo S, Inazawa J, Ooi A.
    Hum Pathol; 2012 Dec 18; 43(12):2229-40. PubMed ID: 22748472
    [Abstract] [Full Text] [Related]

  • 12. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
    Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP.
    J Surg Res; 2007 Nov 18; 143(1):20-6. PubMed ID: 17950068
    [Abstract] [Full Text] [Related]

  • 13. Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population.
    Pala EE, Bayol U, Keskin EU, Ozguzer A, Kucuk U, Ozer O, Koc A.
    Pathol Oncol Res; 2015 Sep 18; 21(4):1223-7. PubMed ID: 26060045
    [Abstract] [Full Text] [Related]

  • 14. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number.
    Sobande F, Dušek L, Matějková A, Rozkoš T, Laco J, Ryška A.
    Cesk Patol; 2015 Sep 18; 51(2):80-6. PubMed ID: 25970719
    [Abstract] [Full Text] [Related]

  • 15. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y.
    Jpn J Clin Oncol; 2012 May 18; 42(5):375-86. PubMed ID: 22450930
    [Abstract] [Full Text] [Related]

  • 16. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y.
    BMC Cancer; 2008 Oct 25; 8():309. PubMed ID: 18950515
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.
    Shao MM, Zhang F, Meng G, Wang XX, Xu H, Yu XW, Chen LY, Tse GM.
    Histopathology; 2011 Aug 25; 59(2):264-73. PubMed ID: 21884205
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
    Vora HH, Patel NA, Thakore PM, Shukla SN.
    Appl Immunohistochem Mol Morphol; 2015 Oct 25; 23(9):653-60. PubMed ID: 25789532
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
    Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H.
    Ann Diagn Pathol; 2018 Aug 25; 35():69-76. PubMed ID: 29843069
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.
    Mrhalova M, Plzak J, Betka J, Kodet R.
    Neoplasma; 2005 Aug 25; 52(4):338-43. PubMed ID: 16059652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.